

2

A (

This application is a continuation of U.S. Patent Application No. 08/625,101, filed April 1, 1996, which issued as U.S. Patent No. 5,869,445; which application is a continuation-in-part of U.S. Patent Application No. 08/414,417, filed March 31, 1995, which issued as U.S. Patent No. 5,801,005; which application is a continuation-in-part of U.S. Patent Application No. 08/106,112, filed on August 12, 1993, abandoned; which application is a continuation-in-part of U.S. Patent Application No. 08/033,644, filed March 17, 1993, abandoned.

In the Claims:

Please amend claim 7 to read as follows:

B2

7. (Twice Amended) A method for eliciting or enhancing an immune response to HER/2-*neu* protein, comprising administering to a warm-blooded animal in an amount effective to elicit or enhance said response a nucleic acid molecule or a viral vector wherein the nucleic acid molecule or the viral vector directs the expression of a polypeptide encoded by a DNA sequence selected from:

- (a) nucleotides 2026 through 3765 of SEQ ID NO:1; and
 - (b) DNA sequences that hybridize to a nucleotide sequence complementary to nucleotides 2026 through 3765 of SEQ ID NO:1 under moderately-stringent conditions, wherein the DNA sequence encodes a polypeptide that produces an immune response to HER-2/*neu* protein and that possesses an amino acid sequence which is identical to a portion of HER-2/*neu* protein and which is approximately the same length as the polypeptide encoded by the DNA sequence of (a).
- what portion

REMARKS

Reconsideration of the application in view of the above amendments and following remarks is respectfully requested.

The specification has been amended to correct a typographical error in the Cross Reference to Related Applications section whereby a prior application was listed as a continuation rather than a continuation-in-part.